Liberate Bio, Inc., a biotechnology company developing genetic medicines that deliver RNA therapies directly to immune cells, announces that it has secured exclusive and non-exclusive licenses to key ...
GlobalData on MSN
Liberate Bio gains licences for myeloid-specific CAR design patents
The intellectual property will enhance Liberate Bio’s LNP platform for selective programming of monocytes and macrophages.
Anatomy explorers have charted a new path myeloid cells use to access the brain. On 3 June in Neuron, scientists led by Lindsay Hohsfield and Kim Green, both at the University of California, Irvine, ...
Research identifies ribosome biogenesis factor MYBBP1A as a driver of acute myeloid leukaemia growth, highlighting a ...
Recent advances in cancer research have underscored the critical role of myeloid cells in shaping tumor microenvironments (TME), influencing tumor progression, immune evasion, and therapeutic ...
Recent advances in cancer research have underscored the critical role of myeloid cells in shaping tumor microenvironments (TME), influencing tumor progression, immune evasion, and therapeutic ...
Mayo Clinic researchers have identified a specific immune cell that can be targeted to give a boost to standard immunotherapies for cancer. Two research teams, working collaboratively but using ...
A comprehensive map of aberrant hematopoiesis in people with acute myeloid leukemia defines specific cell states and potential therapeutic targets. The team used their reference map for normal ...
(RTTNews) - French pharmaceutical company Sanofi S.A. (SNYNF,SNY) said Tuesday that it completed the acquisition of DR-0201, a targeted bispecific myeloid cell engager. Sanofi acquired DR-0201 from a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results